No effective therapy is currently available to promote recovery following ischemic stroke. Stem cells have been proposed as a potential source of new cells to replace those lost due to central nervous system injury, as well as a source of trophic molecules to minimize damage and promote recovery. We undertook a detailed review of data from recent basic science and preclinical studies to investigate the potential application of endogenous and exogenous stem cell therapies for treatment of cerebral ischemia. To date, spontaneous endogenous neurogenesis has been observed in response to ischemic injury, and can be enhanced via infusion of appropriate cytokines. 
In the background of this imperative clinical need, hundreds of studies have recently been published investigating the therapeutic potential of either endogenous or transplanted stem cells in laboratory models of stroke. To their advantage, stem cells have the capacity to respond actively to their environment, migrate to areas of injury, and secrete neuroprotective compounds, in addition to their potential for generating a variety of new functional cell types. Such properties may afford them therapeutic potential both in the acute phase and at later time points after conventional medical therapies would no longer be effective. Here we critically review this body of literature, and conclude that although reconstructing normal brain circuitry following stroke via stem cells is not likely in the foreseeable future, and although great care must be taken to ensure safety before considering clinical trials, preliminary evidence supports the therapeutic potential of certain stem cells for treatment of ischemic brain injury in animal models.
Stem cells: substrate for regeneration
Definitions and types of stem cells. Strictly defined, stem cells possess the cardinal features of multipotency and selfrenewal. Multipotency is the ability to differentiate into multiple functional cell types. Thus stem cells should be able to functionally reconstitute appropriate tissues in vivo. Selfrenewal describes the ability of stem cells to make identical copies of themselves via cell division. At least one daughter cell of a self-renewing cell division must possess the same differentiation and self-renewal potential as the parent cell. Stem cells exhibit extensive proliferation and are often presumed to be able to divide indefinitely, yielding a virtually unlimited supply of cells.
A variety of stem cells can be identified that differ in their potency, or the diversity of cell types they can generate. The ultimate example of "potency" is the zygote, a "totipotent" cell that can therefore give rise to both embryonic and extraembryonic tissues (Hyslop et al., 2005) . However, given that the zygote is transient and does not self-renew, it is not generally regarded as a stem cell. Embryonic stem cells (ESCs) have the broadest potential of any true stem cell. These cells, isolated from the inner cell mass of the blastocyst, are "pluripotent," meaning that they can give rise to all cell types within the developing embryo. Remarkably, the adult mammal also contains a large number of stem cells. These more restricted "tissue-specific" stem cells are capable of generating certain local cell types but not those from unrelated tissues. The best studied tissue-specific stem cell is the hematopoietic stem cell, which is capable of generating all blood cell types. Other tissue-specific stem cells have been identified in numerous organs including muscle, skin, gut, liver, pancreas, and brain. A recent paper described the derivation of ESC-like cells from mouse testes, perhaps suggesting the possibility of obtaining pluripotent cells from the adult organism (Guan et al., 2006) .
Recent studies have demonstrated the induction of pluripotent stem (iPS) cells from terminally differentiated somatic cells via nuclear reprogramming. Takahashi and Yamanaka (2006) systematically transduced mouse fibroblasts with retroviral vectors containing cDNA that encoded one of 24 genes known to be associated with the ESC state. Among these 24 genes they found that transduction with only 4 genes (Oct3/4, Sox2, c-Myc, and Klf4) was sufficient to induce mouse fibroblasts to develop into ES-like cells. Subsequent to this report, Takahashi et al. (2007) were able to extend this finding to human fibroblasts. Thomson and colleagues (Yu et al., 2007) , likewise using human fibroblasts, employed a slightly different combination (Oct4, Sox 2, NANOG, and LIN28) to generate iPS cells, importantly avoiding the proto-oncogene c-myc. Although the effects of using iPS cells have yet to be examined in ischemic brain injury, a recent report by Jaenisch and colleagues (Wernig et al., 2008) 
demonstrates the ability of murine fibroblasts that were reprogrammed to become iPS cells to differentiate into dopamine neurons and correct neurologic deficits in a rat model of Parkinson's disease. All other indications likewise suggest that iPS cells behave identically to embryo-derived ESCs.
Stem cell behavior. In vivo, "true" self-renewing stem cells generally divide infrequently (Morshead et al., 1994) . This feature may help protect the integrity of the genetic material carried by stem cells, as continuous proliferation is associated with increased risk of mutations and possible subsequent tumorgenesis (Miura et al., 2006) . Nevertheless, certain adult tumors are now hypothesized to arise from resident stem cells (Dalerba et al., 2007; Nicolis, 2007) . In order to generate the number of cells required for in vivo regeneration while minimizing stem cell proliferation, adult stem cells undergo asymmetric self-renewing divisions, giving rise to one stem cell and one committed progenitor cell that can proliferate rapidly and thereby give rise to a large number of more differentiated In addition to cell replacement therapy, it is becoming increasingly understood that stem cells also serve supportive roles. For example, certain stem cells appear to exhibit robust tropism for injury. Although most resident cells may die in an injured area, stem cells appear to be attracted to the area of injury and may secrete molecules that promote survival and regeneration (Ourednik et al., 2002) . Stem cells may also be recruited to neoplasms, where they are associated with decreased tumor growth via secretion of antiangiogenic and proinflammatory compounds (Yip et al., 2006) . Several groups are now looking into harnessing stem cells' tropism for injured areas by delivery of stem cells genetically engineered to deliver therapeutic compounds specifically to the area of injury (Muller et al., 2006) . Such an approach may prove particularly relevant for ischemic injuries, in which compromised blood flow may make delivery of such drugs to the affected region more challenging after systemic administration.
Technical considerations for studying neuroregeneration
Neuroregeneration is a relatively new science, and with it have come new insights into techniques initially used in its study Identification of endogenous neurogenesis. One of the most important techniques used in the study of adult neurogenesis involves the labeling of endogenous dividing cells by systemic administration of thymidine analogs such as bromodeoxyuridine (BrdU) and tritiated thymidine. These incorporate into DNA during S-phase of cell division, and can subsequently be identified in the nucleus of any cell born within a few hours after administration. Co-localization of such markers with neuronal proteins such as NeuN is routinely used to identify newly born neurons. A number of considerations apply to the use of thymidine analogs, including dilution of label with continued cell proliferation, toxicity at high doses, and care to ensure unambiguous co-localization via 3D confocal microscopy (Taupin, 2007) . It is also known that normal cells also undergo continual DNA repair, and may thereby take up the label without dividing, although current evidence argues against a detectable level of labeling accumulating through normal DNA repair with short-term administration (Cooper- Kuhn and Kuhn, 2002) . It is of more concern that damaged neurons in ischemic brain regions may re-enter the cell cycle in a process of abortive DNA synthesis prior to dying via apoptosis (Kuan et al., 2004 (Ying et al., 2002) . Thus, the burden of proof now requires demonstration of donor transgenes and the absence of host genetic material in order to prove unambiguously the identity of a transplanted or transdifferentiated cell.
As methodology improves, so does the value of forthcoming conclusions. Thus, although research on regenerative medicine is being subjected to ever-increasing scrutiny, the foundation upon which to build regenerative therapies is becoming increasingly solid.
ENDOGENOUS STEM CELLS AND STROKE Neural stem cells
In spite of decades of dogma proclaiming that no new neurons are born in the adult mammalian brain (Ramó n y Cajal, 1928), an avalanche of data in the past 15 years has confirmed unequivocally that NSCs are in fact present throughout life, and that thousands of new neurons are born daily in the subventricular zone (SVZ) and hippocampus. NSCs can be isolated from the adult brain and cultured in vitro as cellular clusters termed neurospheres in the presence of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) Weiss, 1992, 1996) . Upon cytokine withdrawal, these cells give rise to the three neural cell types: neurons, astrocytes, and oligodendrocytes . Recent in vivo investigations have revealed that NSCs possess features of astrocytes and exist at the end of a developmental continuum starting in the neural tube with neuroepithelial cells, followed by radial glia that serve as both parent and radial migratory guide for newly born neurons in the embryonic brain (Alvarez-Buylla et al., 2001). Although radial glia in most parts of the brain disappear toward the end of development, some persist as multipotent astrocytes in restricted adult brain regions including the SVZ and the subgranular zone (SGZ) of the dentate gyrus (DG), where they are known thereafter as NSCs (Doetsch et al., 1999) . (Fig. 1a,b) . Subsequent evidence has also suggested that resident NSCs in the rostral migratory stream give rise to olfactory bulb neurons, preferentially becoming dopamine (DA)؉ periglomerular cells (Hack et al., 2005) . Although olfactory bulb neurogenesis has been best studied in rodents, there is now evidence that humans likewise harbor NSCs in the SVZ, which migrate along an analogous RMS to a comparatively small olfactory bulb (Curtis et al., 2007) . Nevertheless, the true extent of human adult neurogenesis remains controversial (Sanai et al., 2007) . Moreover, the role of olfactory bulb neurogenesis itself remains to be fully elucidated, although correlative evidence in rodents points toward a role in olfactory memory and discrimination.
Adult neurogenesis

Self
Although there is some debate as to whether NSCs in the hippocampus meet the full criteria of "stem cells" (Morshead and van der Kooy, 2004), it is clear that cells with neurogenic capacity give rise to new neurons throughout life in the DG (Eriksson et al., 1998) (Fig. 1a,c) (Leuner et al., 2006) . The development of new transgenic animal models that, for example, allow selective ablation of newly born neurons may be necessary to address these questions more definitively. Such models will also be critical for the assessment of functional gains observed after induction of neurogenesis in the injured brain.
Ischemia-induced neurogenesis
The finding that the adult brain is home to stem cells with neurogenic potential raises the exciting possibility that such cells may be harnessed to restore neurons and glia to areas damaged by central nervous system (CNS) disease or injury. In this section, we begin with a discussion of the effects of brain injury on SVZ and SGZ NSCs in situ, and then critically review current evidence regarding the presence of newly born neurons in regions of injury. This discussion provides a baseline for subsequent evaluation of techniques to expand and mobilize the NSC pool and thereby augment the endogenous neurogenic response. For the purposes of this discussion, neurogenesis will be defined as the generation of new neurons. Increased proliferation of NSCs, although it often leads to increased neurogenesis, is not a direct measure of neurogenesis, as differentiation of the newly born cells toward a neural lineage is also required. Similarly, increased neurogenesis is not a guarantee that an increase in the net number of functional neurons will be observed, as newly born neurons must first be shown to survive-something that is often tied closely to successful synaptic integration into brain circuitry.
Rodent models of brain ischemia. Several rodent models exist for brain ischemia. Transient bilateral carotid artery stenosis leads to "global ischemia," which selectively destroys specific cell types such as CA1 pyramidal cells in the hippocampus. The more common ischemic models, however, are focal, most often involving occlusion of the middle cerebral artery (MCA), which leads to infarction of the striatum and overlying cortex. Occlusion distal to the striatal branches can be used to generate a selective cortical lesion. Permanent occlusion is accomplished via ligation, cauterization, or laserinduced photothrombosis. Ischemia-reperfusion injury can be modeled via transient occlusion, accomplished by feeding an intraluminal filament through the carotid artery into the proximal MCA. Transient occlusion for a shorter time period (ϳ30 minutes) induces preferential damage to striatal tissue, whereas occlusion for 90 -120 minutes affects both striatum and cortex (Arvidsson et al., 2001) .
Increased neurogenesis in ischemic neurogenic regions. Liu et al. first reported increased hippocampal neurogenesis following global ischemia in 1998. A 12-fold increase in DG cell birth was observed 1-2 weeks after 10 minutes of global ischemia. In this case, neurogenesis represented an amplification of normal neurogenesis rather than induction of neurogenesis in a normally non-neurogenic area. Further, such neurogenesis did not serve to replace the CA1 pyramidal cells lost in global ischemia. Interestingly, neurogenesis in this case was not dependent on actual neuronal cell loss, as ischemic preconditioning, which protects CA1 neurons from subse- In this model, cells die via apoptosis without inflammation, suggesting that cell death itself must be the initiating signal for neuronal replacement. This is in contrast to other injury models in which neurogenesis may be observed even in the absence of neuronal loss. It remains to be determined whether the remarkable fidelity of this regenerative process may reflect the preservation of surrounding parenchyma, but if this is so, it may suggest that similar results may be more challenging to attain in the cavitating lesions following focal ischemia. Further, these results have so far only been obtained by a single lab, and thus await independent confirmation.
Effect of age on neuroregeneration. One criticism of many rodent studies of stroke is that studies are most frequently performed in young adult animals, whereas human stroke pathology most frequently occurs in the aged brain environment. It is well established that both SVZ and DG neurogenesis drop precipitously with age. Thus, one may speculate that a less robust neurogenic response to stroke may be observed in old age. However, several lines of evidence suggest that decreased neurogenesis with age may reflect changes in the brain microenvironment rather than alterations in the numbers or properties of NSCs themselves. Basal levels of corticosteroids increase with age (Sapolsky, 1992) Regulation and augmentation of ischemia-induced neurogenesis. Although there is now little question that neurogenesis occurs in response to ischemic lesions, it seems evident that this endogenous response would need to be bolstered in order for a meaningful level of regeneration to be achieved (Fig. 2) . Indeed, it remains unclear whether baseline levels of stroke-induced neuroregeneration in mammals is of any functional value at all. Such is not the case in all vertebrates. Amphibians and reptiles exhibit robust regeneration of CNS tissue after injury, leading to a brain post injury that is structurally and functionally comparable to the preinjured state. It has been speculated that a paucity of regenerative capacity may be the price paid for increased complexity in the mammalian brain. Nevertheless, a detailed understanding of endogenous neurogenic mechanisms may yield insights into possible methods to enhance neurogenesis following injury. A growing list of physiological stimuli, endogenous molecules, and exogenous agents has been shown to regulate adult neurogenesis. ( To directly assess the contribution of the newly generated cortical tissue to functional recovery, the authors surgically removed the regenerated cortical area and, interestingly, saw loss of behavioral gains at day 7 but not day 1 after removal, suggesting that the new neural tissue may act in a regulatory capacity to promote plasticity or maintain homeostasis of surrounding cortical tissue rather than via direct involvement in motor circuits. Although evidence for mobilization of adult rodent NSCs continues to accumulate, the human brain is much larger and would thus require a far greater number of new neurons, each of which would need to traverse a much greater distance to replace lost cortical tissue (Fig. 2) .
Perhaps the most impressive example of cytokinemediated neuroregeneration following stroke was provided by Nakatomi et al. One study has employed irradiation to attenuate neurogenesis prior to induction of ischemia. Ischemia-induced cognitive deficits were exacerbated by irradiation, which the authors interpreted as evidence that the inhibition of strokeinduced neurogenesis inhibits normal neurogenesis-dependent functional recovery (Raber et al., 2004) . Unfortunately, however, it is difficult to exclude other effects of irradiation, such as the contribution to inflammation that may contribute to the behavioral findings in this experiment. Thus direct evidence for the role of neurogenesis in functional recovery must await the development of transgenic methods to specifically inhibit neurogenesis in parallel-treated animals or to selectively induce apoptosis of new neurons born in response to injury.
Safety considerations in endogenous neurogenesis. Although the beneficial effects of various factors for mobilizing NSCs is cause for great enthusiasm, the potential for unanticipated adverse effects should be investigated with equal rigor. For example, of the first three cytokines discussed above for the mobilization of NSCs, bFGF, EGF, and BDNF, each may be associated with additional effects that would warrant careful consideration before proceeding to clinical trials. 
Neural stem cells in non-neurogenic regions?
Many of the above studies have shown convincing evidence of neuroblast migration from the SVZ or RMS to areas of injury. However, in several studies, it has been difficult to exclude the possibility that some newly generated neuronal cells may be born locally. Although there is presently limited evidence for normal neurogenesis in most parts of the brain, cells can be isolated from multiple regions of the brain (including cerebellum, cortex, white matter, and spinal cord) that possess NSC properties in vitro, being capable of differentiation into neurons, astrocytes, and oligodendrocytes. The exact identity of these cells remains uncertain, and could include quiescent NSCs, or glial cells that exhibit neural potential under certain conditions. Indeed, oligodendrocyte pre- 
EXOGENOUS STEM CELLS Introduction to cell transplantation
The majority of studies to date have shown relatively limited cell replacement from endogenous NSCs. Further, the technology for mobilizing endogenous NSCs is relatively new. In contrast, work has been in progress for decades to replace lost neural cells by transplantation of either fetal brain tissue (Bjorklund and Stenevi, 1979; Perlow et al., 1979) or, more recently, stem cells. Potential advantages to this approach may include greater control over cell fate, the ability to deliver any desired number of cells, and reduced risks associated with mitogen infusion. A number of different cell types have been considered for cell transplantation with goals ranging from replacement of host circuitry to delivery of neuroprotective or immunomodulatory compounds. Before expounding on specific cell types, however, we briefly discuss basic issues related to cell transplantation in general. Pretreatment. The most common fate of transplanted cells is cell death (Bakshi et al., 2005; Burns et al., 2006) . Although this may be less of a concern with stem cell-derived cells than fetal tissue, which may be in more limited supply, having large numbers of dead cells in the graft may exacerbate stroke-related deficits (Modo et al., 2003) . Differentiation toward a neural lineage itself is also directly associated with cell death, and this may be especially true in a non-neurogenic region lacking necessary neurotrophic cues. Thus various methods have been developed both to block apoptotic programs and to prevent their initiation via provision of various neurotrophic compounds (Sortwell, 2003) .
Delivery variables
Scaffolds. Even upon the successful differentiation and survival of neurons, the ischemic environment presents particular challenges to functional restoration. A large infarct is associated with massive necrosis and may yield an infarct core that is inhospitable to newly delivered cells due to lack of blood supply and absence of an appropriate extracellular support. One approach has involved the transplantation of NSC-embedded scaffolding into the infarct cavity to promote the formation of reciprocal connections between graft and host. Although favorable results have been suggested, further studies are needed to assess this technique more critically (Park et al., 2002) . 
Genetic stability
CONCLUSIONS
Although we may never be able to "regrow" large areas of brain lost to stroke, stem cell technology is a rapidly evolving field that will likely significantly impact the future treatment of ischemic brain injury. It is now clear that NSCs exist in the brain and undergo limited neurogenesis in response to stroke. Proof of principle exists that this endogenous response may be substantially augmented through the delivery of appropriate cytokines. Exogenous stem cells offer the complementary advantages of being available in unlimited numbers with additional control over fate, cell number, timing, and site of delivery. The fact that substantial functional gains have been observed in animal models after delivery of cells of both neural and non-neural origin in preclinical models of ischemic brain injury is encouraging. Nevertheless, caution is indicated to ensure the highest standards of safety and scientific rigor as this exciting field moves forward.
